Lyra’s stock soars on Phase 3 success for chronic rhinosinusitis treatment
Lyra Therapeutics’ shares shot up about 500% at market open on Monday after the biotech said its nasal implant improved signs of an inflammatory sinus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
